Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.
immunotherapy
multiple myeloma
relapsed refractory
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
04
10
2021
revised:
14
11
2021
accepted:
18
11
2021
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.
Identifiants
pubmed: 35846211
doi: 10.1002/jha2.359
pii: JHA2359
pmc: PMC9175681
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-128Informations de copyright
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Int J Hematol. 2019 Nov;110(5):559-565
pubmed: 31392600
Blood. 2013 Aug 15;122(7):1243-55
pubmed: 23823317
Leuk Lymphoma. 2020 Dec;61(13):3255-3258
pubmed: 32772601
Cells. 2020 Mar 03;9(3):
pubmed: 32138182
Int J Hematol. 2019 Jun;109(6):665-672
pubmed: 30963473
J Oncol. 2019 Nov 3;2019:6084012
pubmed: 31781214
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Immunol Today. 1994 Mar;15(3):95-7
pubmed: 8172650
Anticancer Res. 2019 Sep;39(9):5165-5170
pubmed: 31519629
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861548
Leuk Res. 2004 May;28(5):469-77
pubmed: 15068900
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Ann Hematol. 2019 Jun;98(6):1435-1440
pubmed: 30874850
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
N Engl J Med. 2015 Sep 24;373(13):1207-19
pubmed: 26308596
Am J Hematol. 2017 Nov;92(11):1146-1155
pubmed: 28799231
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Ther Adv Hematol. 2019 Jan 18;10:2040620718822660
pubmed: 30719268
J Clin Oncol. 2010 Feb 10;28(5):830-4
pubmed: 20038719
Cell Immunol. 1996 Nov 1;173(2):192-7
pubmed: 8912876
Ann Hematol. 1992 Mar;64(3):132-9
pubmed: 1373957
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Leukemia. 2014 Jun;28(6):1346-8
pubmed: 24418994
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480
Adv Med Sci. 2019 Sep;64(2):349-355
pubmed: 31125864